Home> Industry News >Trend >Main Body

  • Industry News

Alder Reports Phase 2b Trial of ALD403 Meets Primary and Secondary Endpoints Demonstrating Migraine Prevention in Patients with Chronic Migraine

2016-03-29 09:34
yahoo
Read:175 Favorite  0
  Share
相关阅读
You may interest

Copyright©2020 药渡经纬信息科技(北京)有限公司 电子与信息服务业务经营许可证151001号

京ICP备14047345| 京公安网备11010802017043号 |(京)-经营性-2015-0023(互联网药品信息服务资格证书)

药渡APP Drug A-Z
药渡APP
药渡微信二维码
微信二维码